Q-omics provides the consensus-scored RASAL2-AS1 profile across patient tissues and cancer cell-line models. RASAL2-AS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RASAL2-AS1 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, RASAL2-AS1 RNA expression shows 18,650 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, LIHC, and ACC as cancer lineages where RASAL2-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASAL2-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASAL2-AS1 survival associations across molecular data types. RASAL2-AS1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASAL2-AS1 RNA expression–survival associations across cancer types. High RASAL2-AS1 expression shows unfavorable associations in BLCA, ACC, MESO and LGG, but favorable associations in UCS and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RASAL2-AS1 RNA expression.
This table summarizes RASAL2-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RASAL2-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASAL2-AS1 shows lower tumor expression in KICH and LUAD and higher tumor expression in LIHC, COAD, HNSC and STAD. The LIHC box plot shows higher RASAL2-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.514, t-test p < 0.001).
This table shows molecular features associated with RASAL2-AS1 in patient tissues and cancer cell lines. In patient samples, RASAL2-AS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
